Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Scientific research into psychedelic substances is entering a new phase. A recent analysis of registered clinical trials shows that research on ayahuasca and its main psychoactive component DMT is increasing markedly worldwide. The number of trials has risen sharply above all since 2020 and 2021.
The review covers 26 registered clinical trials on DMT, ayahuasca, and combinations with the compound harmine (a beta-carboline). Most of the studies are still in the early stages of drug development. Safety questions come first: researchers are mainly examining tolerability, effects on the cardiovascular system and on mental state, as well as the subjective changes in consciousness after intake.
According to the analysis, it is striking that the trials are conducted predominantly with physically and mentally healthy adults. People with psychiatric conditions or heart problems are usually excluded. That suggests the field continues to proceed cautiously and to keep risks as low as possible.
The scientific publications available so far concentrate above all on controlled administration, suitable dosing, and possible mechanisms of action. Early smaller studies in the field of depression also offer indications that DMT-based therapies could hold therapeutic potential. Larger and strictly controlled trials would be needed, however, before firm conclusions can be drawn.
Overall, the authors of the analysis speak of an “active and maturing field of research”. At the same time, they note that clinical programs for conditions other than depression are still missing. Despite the growing momentum, the development of psychedelic therapies is therefore still at an early stage.
